TY - JOUR T1 - The utility of gallium-68 DOTATOC PET/CT in lymphangioleiomyomatosis JF - ERJ Open Research JO - erjor DO - 10.1183/23120541.00397-2021 VL - 7 IS - 4 SP - 00397-2021 AU - Brian Gaffney AU - Evelyn Lynn AU - Jonathan D. Dodd AU - Michael P. Keane AU - David J. Murphy AU - Cormac McCarthy Y1 - 2021/10/01 UR - http://openres.ersjournals.com/content/7/4/00397-2021.abstract N2 - Lymphangioleiomyomatosis (LAM) is a progressive, low-grade, metastasising neoplasm of women that is characterised by infiltration of the lung parenchyma with abnormal smooth muscle-like cells, resulting in cystic lung destruction [1]. While forced expiratory volume in 1 s (FEV1) is the current standard outcome measure used in LAM, there are limitations to its use as a true surrogate of disease severity and it may underestimate disease burden. Additionally, pulmonary function testing depends on patient cooperation and there can be significant intertest variation. Despite vascular endothelial growth factor (VEGF)-D being an excellent diagnostic test and biomarker of prognosis [2], it is not elevated in all patients; hence, other biomarkers of disease activity and prognosis are required.Somatostatin receptor functional imaging is of limited utility as an imaging biomarker in LAM, but other PET/CT modalities may be of use https://bit.ly/3l6BVZp ER -